Weight-Loss Drugs Protect Knees
University of Maryland study finds weight-loss drugs can significantly reduce need for knee replacement surgery.
Weight-loss drugs like Ozempic and Wegovy could prevent thousands of knee replacement surgeries every year, a major new study suggests. Researchers at the University of Maryland School of Medicine found that patients who took GLP-1 medications for at least three years had a 4.7 percentage point lower risk of needing knee surgery within eight years, according to The Guardian.
If all eligible patients with knee arthritis and obesity took semaglutide or tirzepatide for three years, up to 14,400 fewer knee replacements could happen annually in the US and more than 1,500 fewer in the UK, the study projects. The findings were published in the journal Regional Anesthesia & Pain Medicine, MedPage Today reported.
What the Study Found and How It Was Done
Researchers tracked 6.8 million adults diagnosed with knee osteoarthritis between 2010 and 2024. They compared 42,000 people who had taken a GLP-1 drug for one year against those who had not. Even one year of use was linked to a 1.4 percentage point lower risk of surgery at the three-year mark, according to The Guardian.
The benefits grew with longer treatment. Three years of GLP-1 use cut the surgery risk by 4.7 percentage points by the eight-year follow-up. Lead researcher Dr. Jay Karri said the results are "consistent with the possibility of effects beyond symptomatic relief or weight loss alone," MedPage Today reported.
Why These Drugs May Protect Joints Beyond Weight Loss
Losing weight takes pressure off painful knees. But researchers think GLP-1 drugs may do more than that. They may also fight inflammation directly inside the joint. Mark Bowditch, immediate past president of the British Orthopaedic Association, said the drugs may have "direct anti-inflammatory and possibly cartilage-protective effects," according to The Guardian.
This idea is called "joint tissue modulation." It suggests GLP-1s may slow the breakdown of cartilage caused by metabolic disease — not just by reducing body weight. Knee osteoarthritis affects roughly 14 million people in the US and 5 million in the UK, making the stakes for any disease-modifying treatment enormous.
Experts Urge Caution: Association Is Not Proof of Cause
Not everyone is ready to declare victory. Bowditch warned that the Maryland study shows an association, not a direct cause. Patients taking these drugs may also eat better, exercise more, or attend physical therapy — all of which could independently lower their need for surgery, The Guardian noted.
There are also bone health concerns. Rapid weight loss can sometimes reduce bone density, which could create new problems for joint stability down the line. Researchers at Michigan State University presented data in March 2026 warning of potential risks including osteoporosis in long-term GLP-1 users, according to The Independent.
Huge Cost Savings Possible, but Drug Prices Complicate Picture
A total knee replacement can cost $30,000 to $50,000 per procedure. Cutting 14,400 surgeries a year in the US alone could save hundreds of millions of dollars. But GLP-1 drugs can cost up to $1,300 per month, meaning the net savings depend heavily on how long patients stay on treatment and how drug prices change.
Policy implications are also significant. In the UK, weight-loss drugs are mostly available only through specialist NHS services. Evidence that they prevent expensive surgeries could push policymakers to make them more widely available at lower tiers of care, The Independent reported.
Sentiment
NeutralPublishers
5
Articles
3
Reach
6
